OverviewChartNewsTraderScreen

Morgan Stanley Call 900 REGN 20.1.../  DE000ME6VGN2  /

Stuttgart
2024-05-15  6:02:11 PM Chg.-0.23 Bid9:01:53 PM Ask9:01:53 PM Underlying Strike price Expiration date Option type
6.15EUR -3.61% 6.29
Bid Size: 5,000		 6.48
Ask Size: 5,000		 Regeneron Pharmaceut... 900.00 USD 2024-12-20 Call
GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire 05-14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire 05-10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire 05-09 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire 05-08 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire 05-07 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire 05-06 Regeneron Announces Investor Conference Presentations
GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire 04-26 Medigene AG reports Financial Results and Business Update for Q1 2024
GlobeNewswire 04-25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire 04-23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire 04-22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire 04-18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...
GlobeNewswire 04-18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...
GlobeNewswire 04-16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
GlobeNewswire 04-16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire 04-15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
GlobeNewswire 04-11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...
GlobeNewswire 04-09 Opthea Appoints John Han, PharmD, as VP Medical Affairs
GlobeNewswire 04-07 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire 04-01 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire 03-25 Regeneron Provides Update on Biologics License Application for Odronextamab